Skip to main content Skip to section navigation Skip to footer
French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
    • Grace Merger Conference Call
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
  • Grace Merger Conference Call

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023

Acasti Announces Appointment of Prashant Kohli as CEO

Apr 4, 2023

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 30, 2023

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 13, 2023

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023

Acasti Pharma Recognizes Rare Disease Day

Feb 28, 2023

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 14, 2023

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Feb 7, 2023
rss_feed News RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2023 Acasti Pharma Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap